{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"1"},{"groupId":"OG003","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"50"}],"units":"Participants"}],"description":"Laboratory abnormality criteria included: hemoglobin (HGB); hematocrit; erythrocytes \\< 0.8\\*lower limit of normal (LLN); erythrocyte mean corpuscular volume/HGB/ HGB concentration, erythrocytes distribution width \\<0.9\\*LLN, \\>1.1\\*upper limit of normal (ULN); platelets \\<0.5\\*LLN,\\>1.75\\* ULN; leukocytes\\<0.6\\*LLN, \\>1.5\\*ULN; lymphocytes, neutrophils \\<0.8\\*LLN, \\>1.2\\*ULN; basophils, eosinophils, monocytes \\>1.2\\*ULN; total bilirubin\\>1.5\\*ULN; activated partial thromboplastin time, prothrombin time, prothrombin intl. normalized ratio \\>1.1\\*ULN; bilirubin \\>1.5\\*ULN; aspartate aminotransferase (AT), alanine AT, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase \\>3.0\\*ULN; protein; albumin\\<0.8\\*LLN, \\>1.2\\*ULN; urea nitrogen, creatinine, cholesterol, triglycerides \\>1.3\\*ULN; urate \\>1.2\\*ULN; sodium \\<0.95\\*LLN,\\>1.05\\*ULN; potassium, chloride, calcium, magnesium, bicarbonate \\<0.9\\*LLN, \\>1.1\\*ULN; phosphate \\<0.8\\*LLN, \\>1.2\\*ULN; Urine: glucose, ketones, protein, HGB, bilirubin, nitrite \\>=1.","groups":[{"description":"Participants received placebo matched to tanezumab SC once every 8 weeks for 24 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants in this discontinued treatment arm, received tanezumab 10 mg SC once every 8 weeks before protocol amendment 3 and completed their treatment before the amendment.","id":"OG001","title":"Tanezumab 10 mg"},{"description":"Participants in this treatment group had received tanezumab 10 mg SC once every 8 weeks before protocol amendment 3 and after the amendment they continued remaining treatment with tanezumab 20 mg SC once every 8 weeks.","id":"OG002","title":"Tanezumab 10/20 mg"},{"description":"Participants received tanezumab 20 mg SC once every 8 weeks for 24 weeks.","id":"OG003","title":"Tanezumab 20 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety analysis set was analyzed. Here, \"Overall Number of Participants Analyzed\" signifies participants with a normal baseline with at least one observation of the given laboratory test while on the study. There were no participants in reporting arm \"Tanezumab10/20 mg\", who met the criteria for data collection and analysis of this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1, before dosing) up to Week 48","title":"Number of Participants With Laboratory Abnormalities (Normal Baseline)","type":"SECONDARY","unitOfMeasure":"Participants"}